Replies to post #149701 on Biotech Values

[turtlepower]

The MOS for the erlotinib control arm is assumed to be 7 months. So unless they have sicker patients in the trial the alternative has to be bearish if the interim is much earlier than expected.

[jq1234]

I agree. I don't pay much attention to projected timeline unless it is way way off mark.